<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825123</url>
  </required_header>
  <id_info>
    <org_study_id>141/07 bayside health</org_study_id>
    <nct_id>NCT00825123</nct_id>
  </id_info>
  <brief_title>Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals</brief_title>
  <official_title>The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine the effects of slowing heart rate upon both
      central and peripheral blood pressures using Ivabradine. The effects of Ivabradine will be
      compared to Metoprolol and placebo.

      Participants will attend the hospital for 3 visits where they will be randomised to receive
      either Ivabradine, Metoprolol and placebo on each visit. Non-invasive measures of blood
      pressure will be recorded before and after consuming the study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will undergo three days of laboratory testing, each visit separated by at least
      seven days.

      In order to assess each potential participant's suitability for the study based upon the
      relevant inclusion and exclusion criteria, the first visit will involve a medical
      consultation (history and physical examination), venepuncture (for full blood examination,
      lipid profile and biochemistry) and a 12-lead surface electrocardiogram. Baseline
      measurements of central and peripheral arterial and pulse wave velocity will be made at
      baseline, and 4 hours following the administration of either placebo, 50mg of metoprolol or a
      10mg oral dose of ivabradine. The placebo will contain lactose powder.

      Subjects will be randomized according to a 3-by-3 Latin square design. Central pulse pressure
      will be assessed using carotid artery tonometry using a non-invasive Millar Mikro-tip
      pressure transducer. The transducer is used to applanate the carotid artery and calibrated
      using brachial mean and diastolic blood pressure (automated oscillometric sphygmomanometer).

      Pressure waveforms will also be recorded at the radial, brachial and femoral arteries to
      permit study of wave reflection at these sites.

      Measurements will be taken be taken before and 4 hours following the oral administration of
      metoprolol/ivabradine/placebo.

      Bias will be minimized by blinding both the participants and research staff responsible for
      data collection to the administered drug.

      Any potential patient-specific confounding factors will have minimal impact, as the same
      participants will be studied after the administration of the three agents.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>central arterial pressure</measure>
    <time_frame>baseline and 4 hours post treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Central Arterial Pressure</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 10 mg once</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Coralan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol 50 mg once</description>
    <arm_group_label>Metoprolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers:

          -  aged 18 - 25 years OR

          -  aged &gt;60 years

        Exclusion Criteria:

          -  Chronic disease

          -  Unable to give informed consent

          -  Treated or untreated systemic arterial hypertension (SBP &gt;160mmHg and/or DBP &gt; 90mmHg)

          -  Resting bradycardia (heart rate &lt; 60 beats/minute)

          -  Pregnancy or active lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bronwyn A Kingwell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Hearte &amp; Diabetes Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2009</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>A/Prof Bronwyn Kingwell</name_title>
    <organization>Bakere IDI Heart &amp; Diabetes Institute</organization>
  </responsible_party>
  <keyword>healthy individuals</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

